R&D Pipeline

 

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions. 

Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.

Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Skin Cancer
1L Metastatic Melanoma
Bempegaldesleukin + OPDIVO®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT03635983
STUDY PIVOT-IO-001
+
Genitourinary Cancer
1L Metastatic Renal Cell Carcinoma
Bempegaldesleukin + OPDIVO®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT03729245
STUDY PIVOT-09
+
Genitourinary Cancer
Muscle-Invasive Bladder Cancer Who Are Cisplatin Ineligible
Bempegaldesleukin + OPDIVO®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT04209114
STUDY PIVOT-IO-009
+
Skin Cancer
Adjuvant Melanoma
Bempegaldesleukin + OPDIVO®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT04410445
STUDY PIVOT-12
+
Head and Neck Cancer
1L Metastatic Head and Neck Squamous Cell Carcinoma
Bempegaldesleukin + KEYTRUDA®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 3 Registrational
Agent(s) Bempegaldesleukin + KEYTRUDA®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT04969861
STUDY PROPEL-36
+
Genitourinary Cancer
1L Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Cancer
Bempegaldesleukin + OPDIVO®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 2 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT03785925
STUDY PIVOT-10
+
Genitourinary Cancer
1L Advanced Renal Cell Carcinoma
Bempegaldesleukin + OPDIVO® + TKI
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1 + TKI
Phase 2
Agent(s) Bempegaldesleukin + OPDIVO® + TKI
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1 + TKI
NCT# NCT04540705
STUDY PIVOT-IO-11
+
Lung Cancer
1L Metastatic Non-Small Cell Lung Cancer
Bempegaldesleukin + KEYTRUDA®
CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
Phase 2
Agent(s) Bempegaldesleukin + KEYTRUDA®
Mechanism CD122-Preferential IL-2 Pathway Agonist + Anti-PD-1
NCT# NCT03138889
STUDY PROPEL
+
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Bempegaldesleukin + VB10.NEO
CD122-Preferential IL-2 Pathway Agonist + Cancer Vaccine
Phase 1
Agent(s) Bempegaldesleukin + VB10.NEO
Mechanism CD122-Preferential IL-2 Pathway Agonist + Cancer Vaccine
NCT# NCT03548467
STUDY DIRECT-01
+
Solid Tumors
Relapsed/Refractory Metastatic Melanoma
NKTR-262 + Bempegaldesleukin
TLR 7/8 Agonist + CD122-Preferential IL-2 Pathway Agonist
Phase 1/2
Agent(s) NKTR-262 + Bempegaldesleukin
Mechanism TLR 7/8 Agonist + CD122-Preferential IL-2 Pathway Agonist
NCT# NCT03435640
STUDY REVEAL
+
Hematological Cancer
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NKTR-255 + RITUXAN® or DARZALEX FASPRO®
IL-15 Pathway Agonist + Anti-CD20 or Anti-CD38
Phase 1/2
Agent(s) NKTR-255 + RITUXAN® or DARZALEX FASPRO®
Mechanism IL-15 Pathway Agonist + Anti-CD20 or Anti-CD38
NCT# NCT04136756
+
Solid Tumors
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
NKTR-255 + ERBITUX®
IL-15 Pathway Agonist + epidermal growth factor receptor (EGFR) antagonist
Phase 1/2
Agent(s) NKTR-255 + ERBITUX®
Mechanism IL-15 Pathway Agonist + epidermal growth factor receptor (EGFR) antagonist
NCT# NCT04616196
+
Autoimmune Disorders
Systemic Lupus Erythematosus
NKTR-358
IL-2 T Regulatory Cell Stimulator
Phase 2
Agent(s) NKTR-358
Mechanism IL-2 T Regulatory Cell Stimulator
NCT# NCT04433585
STUDY ISLAND-SLE
+
Autoimmune Disorders
Ulcerative Colitis
NKTR-358
IL-2 T Regulatory Cell Stimulator
Phase 2
Agent(s) NKTR-358
Mechanism IL-2 T Regulatory Cell Stimulator
NCT# NCT04677179
STUDY INSTRUCT-UC
+
Autoimmune Disorders
Psoriasis
NKTR-358
IL-2 T Regulatory Cell Stimulator
Phase 1B
Agent(s) NKTR-358
Mechanism IL-2 T Regulatory Cell Stimulator
NCT# NCT04119557
+
Autoimmune Disorders
Atopic Dermatitis
NKTR-358
IL-2 T Regulatory Cell Stimulator
Phase 1B
Agent(s) NKTR-358
Mechanism IL-2 T Regulatory Cell Stimulator
NCT# NCT04081350
+
Viral Diseases
COVID-19
Bempegaldesleukin
CD122-Preferential IL-2 Pathway Agonist
Phase 1
Agent(s) Bempegaldesleukin
Mechanism CD122-Preferential IL-2 Pathway Agonist
NCT# NCT04646044
+

Read About Nektar's Research Platform

View Medicines Marketed by Nektar's Partners

View Our Scientific & Medical Events Calendar